LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Kodu・Aktsiate loetelu・AbCellera Biologics Inc

AbCellera Biologics Inc

Suletud

SektorTervishoid

3.68 1.94

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.64

Max

3.7

Põhinäitajad
By Trading Economics
Sissetulek	-22M -57M
Müük	-8.1M 9M
Aktsiakasum	-0.19
Kasumimarginaal	-637.845
Töötajad	596
EBITDA	-25M -64M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+51.93% upside

Turustatistika
By TradingEconomics
Turukapital	-398M 1.2B
Eelmine avamishind	1.74
Eelmine sulgemishind	3.68

Uudiste sentiment

By Acuity

56%

44%

291 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.99 / 2.635 Toetus ja vastupanu

AbCellera Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2025, 17:45 UTC

Tulu

Suurimad hinnamuutused turgudel

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. nov 2025, 17:31 UTC

Tulu

Suurimad hinnamuutused turgudel

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

15. nov 2025, 18:03 UTC

Tulu

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- UPDATED -- WSJ

15. nov 2025, 15:43 UTC

Tulu

Kugler Resignation From Fed Board Followed Disclosures of Improper Stock Trades -- WSJ

15. nov 2025, 12:00 UTC

Tulu

Meta Opens Pop-Up Stores to Build Buzz for Its AI Glasses -- WSJ

15. nov 2025, 09:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

15. nov 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15. nov 2025, 00:08 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14. nov 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. nov 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. nov 2025, 22:35 UTC

Tulu

Omandamised, ülevõtmised, äriostud

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. nov 2025, 22:32 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. nov 2025, 22:29 UTC

Tulu

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. nov 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. nov 2025, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

14. nov 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. nov 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. nov 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. nov 2025, 20:17 UTC

Omandamised, ülevõtmised, äriostud

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. nov 2025, 19:29 UTC

Market Talk

Tulu

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. nov 2025, 18:44 UTC

Market Talk

Tulu

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. nov 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. nov 2025, 17:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

14. nov 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

14. nov 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. nov 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. nov 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14. nov 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

Võrdlus sarnastega

Hinnamuutus

AbCellera Biologics Inc Prognoos

Hinnasiht

By TipRanks

51.93% tõus

12 kuu keskmine prognoos

Keskmine 5.5 USD 51.93%

Kõrge 7 USD

Madal 4 USD

Põhineb 4 Wall Streeti analüütiku instrumendi AbCellera Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi AbCellera Biologics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.99 / 2.635Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

291 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.